GE Board Approves Proposed Spin-off Of GE HealthCare

General Electric Co. (GE) announced Thursday that its Board of Directors has approved its proposed spin-off of its healthcare business, GE Healthcare Holding LLC.

Prior to such spin-off, GE HealthCare would be converted into a corporation and renamed GE HealthCare Technologies Inc. The company is expected to begin trading on Nasdaq on January 4, 2023, under the ticker "GEHC".

Following the spin-off, GE will retain up to 19.9% of the outstanding shares of GE HealthCare common stock.

To effect the separation, GE's Board approved a distribution to GE shareholders of at least 80.1% of the outstanding shares of GE HealthCare.

The company noted that its stock holders will be entitled to receive one share of GE HealthCare stock for every three GE shares owned on December 16, the record date for the distribution.

The distribution is expected to occur after U.S. market close on January 3.

GE Chairman and CEO, GE Aerospace CEO, Lawrence Culp, Jr. said, "Today's announcement marks one of the final milestones for our planned spin-off of GE HealthCare as we move toward launching three independent, industry-leading, and investment-grade companies."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT